Navigation Links
Ardea Biosciences Reports Recent Accomplishments and Second Quarter 2011 Financial Results

partially offset by an increase in weighted-average shares outstanding in 2011 as a result of our April 2010 and February 2011 public offerings of common stock.ARDEA BIOSCIENCES, INC.Condensed Consolidated Statements of Operations(in thousands, except per share amounts)Three Months Ended

June 30,

(Unaudited)Six Months Ended

June 30,

(Unaudited)2011201020112010Revenues: License fees





4,853 Sponsored research132—222— Reimbursable research and development costs9671,0951,5711,942Total revenues2,1763,5213,9466,795Operating expenses: Research and development15,52712,88428,24223,135 General and administrative4,7693,3199,0186,246Total operating expenses20,29616,20337,26029,381Loss from operations(18,120)(12,682)(33,314)(22,586)Other income (expense): Interest income98111205180 Interest expense(98)(229)(232)(490) Other income, net613926Total other income (expense)6(105)(18)(284)Net loss





(22,870)Basic and diluted net loss per share





(1.11)Shares used in computing basic and diluted net loss per share 26,68722,55626,24120,568Condensed Consolidated Balance Sheet Data(in thousands)June 30,


(unaudited)December 31,

2010Cash, cash equivalents and short-term investments



80,612Total assets



100,454Total stockholders' equity



77,123About Ardea Biosciences, Inc.Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases. Lesinurad (RDEA594), our lead product candidate for the chronic management of hyperuricemia in patients with gout, is a once-daily, oral inhibitor of the URAT1 transporter.

SOURCE Ardea Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Ardea Biosciences to Present at Upcoming Investor Conferences
2. Ardea Biosciences Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at 2011 American Society of Clinical Oncology Annual Meeting
3. Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results
4. Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2010 Financial Results
5. Ardea Biosciences Announces Exercise in Full of Overallotment Option for Common Stock Offering
6. Ardea Biosciences Prices Public Offering of Common Stock
7. Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
8. Ardea Biosciences to Present at Two Upcoming Investor Conferences
9. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
10. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
11. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
Post Your Comments:
(Date:10/8/2015)... , Oct. 8, 2015  Sigma-Aldrich Corporation (NASDAQ: ... ® brand within its Applied Diagnostics and ... acid reference standards product line with ten certified ... tested bile acids and their stable-labeled internal standards. ... of lithocholic acid, taurocholic acid and native and ...
(Date:10/8/2015)... ... 08, 2015 , ... ProMIS Neurosciences, Inc. (TSX: PMN), announced ... commercialize intellectual property rights belonging to The University of British Columbia (UBC). This ... worldwide rights to intellectual property based on use of the ProMIS™ technology, modifications ...
(Date:10/7/2015)... India , October 8, 2015 /PRNewswire/ ... --> Medical biotechnology accounts for largest ... of bioinformatics in drug discovery and development ... . ... On the basis of applications, the ...
(Date:10/7/2015)... ... 07, 2015 , ... Neil Riordan, PhD to Discuss Medicinal Effects of Mesenchymal ... Mar-a-Lago from 3:50 pm to 4:30 pm. , Dr. Riordan is one of the ... He is the Co-Founder and Chief Science Officer of the Riordan-McKenna Institute ...
Breaking Biology Technology:
... HARBIN, China , May 12 ... One Medical" or "the Company") (Nasdaq: CSKI ), ... Republic of China ,("PRC"), today provided an update on ... additional market research and customer feedback, the,Company estimates aggregate ...
... May 12 Sagent Pharmaceuticals, Inc., ... FDA approval of bacitracin for injection, USP (bacitracin), ... empyema. Bacitracin will be offered in a 50,000 ... individually and in packages of ten.  These vials ...
... , May 12 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY ) ... will present at the Rodman & Renshaw Annual Global Investment Conference taking place ... , , ... British Summer Time ( 5:15 a.m. Eastern Daylight Time ) on Tuesday, ...
Cached Biology Technology:
(Date:9/2/2015)... 2015 Security of data and assets ... government organizations, telecommunications, hospitals, as well as individuals. ... being used to prevent unauthorised access. Technological advancements ... individuals could gain access to secure premises after ... hardware devices and numeric codes. However, hackers also ...
(Date:9/1/2015)... 1, 2015  Automation and pre-processing are reducing ... screening. This is the first step toward a ... become unintrusive. An assortment of portal scanners, biometric ... investigations will transform the passenger screening process. ... Global Airport Passenger Screening Market ( ...
(Date:8/31/2015)... Research and Markets ( ) has ... Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... Arabia Biomedical Sensors market is estimated at $0.23 billion ... period 2014-2020 The near future will bring ... of each individual. These sensors can be set to ...
Breaking Biology News(10 mins):
... Amyloid-beta and tau protein deposits in the brain are ... hippocampus, the area of the brain that plays a ... However, it appears that the toxic effect of tau ... is switched off. Researchers from the Max Planck Research ...
... Israel,s Wolf Foundation, whose stated mission is "to promote ... named Whitehead Institute Founding Member Rudolf Jaenisch a recipient ... Jaenisch will share this year,s prize with Kyoto University,s ... "their groundbreaking contribution to stem cell research." ...
... Jan. 12, 2011 The agreement grants DSM ... and secures supply of Codexis enzymes for commercialization ... DSM,s InnoSyn™ route scouting services. Codexis ... for active pharmaceutical ingredients and intermediates which reduce ...
Cached Biology News:
... comprehensive epitope analysis service utilizing high ... microfluidic chips for immunological studies, vaccine ... service includes assistance with your sequence ... by you, single or dual color ...
... aptamer screening and binding optimization and built ... on-chip synthesis platform. Thousands of customer specified ... LC Sciences can provide assistance with custom ... part of our comprehensive DNA/RNA Aptamer Microarray ...
... commonly used as a fusion partner when ... GSTTag sequence has been reported to enhance ... solubility of its fusion partners. When expressed ... fusion proteins can be purified with immobilized ...
... glutathione-S-transferase (GST) is commonly used as a ... coli (1). The GSTTag sequence has been ... some cases the solubility of its fusion ... folded form, GSTTag fusion proteins can be ...
Biology Products: